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Background-—Growth differentiation factor-15 (GDF-15) is related to major bleeding when measured at initial presentation in
patients with acute coronary syndromes (ACSs) treated with dual antiplatelet therapy. It is unknown whether follow-up
measurements provide additional information. The objective of this study was to investigate whether GDF-15 measured 1 month
after an ACS provides additional information beyond the baseline levels with regard to the risk of major bleeding.
Methods and Results-—GDF-15 was measured at baseline and at 1 month after an ACS in 4049 patients included in the PLATelet
inhibition and patient Outcomes (PLATO) trial. The association between 1-month GDF-15 level and non–coronary artery bypass
grafting surgery-related major bleeding was assessed by a multivariable Cox model, adjusting for baseline GDF-15, age, anemia,
impaired renal function, history of gastrointestinal bleeding, and sex. Elevated GDF-15 (>1800 ng/L) at 1 month was associated
with an increased risk of non-coronary artery bypass grafting-related major bleeding (3.9% versus 1.2%; hazard ratio, 3.38; 95% CI,
1.89–6.06), independent of baseline GDF-15. Patients who had elevated GDF-15 levels at baseline and subsequent nonelevated
GDF-15 at 1 month had a similar risk as patients who had nonelevated levels at both measurements.
Conclusions-—GDF-15 at 1 month after an ACS is related to the risk of bleeding during DAPT and provides additional information
on the bleeding risk beyond baseline GDF-15 levels. GDF-15 levels may therefore be useful as part of decision support concerning
long-term antithrombotic treatment in patients post-ACS.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT00391872. ( J Am Heart Assoc. 2017;6:
e005580. DOI: 10.1161/JAHA.117.005580.)
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A ntithrombotic therapy is a cornerstone in the manage-ment of patients with acute coronary syndrome (ACS).
Intense platelet inhibition in the acute phase and for 1 year
after percutaneous coronary intervention (PCI) is associated
with decreased rates of ischemic events, but at the cost of
higher rates of bleeding.1–3 Recent studies have shown
further reduction in ischemic events by dual antiplatelet
therapy (DAPT) beyond 1 year after an ACS and PCI.4–6
Patients with ACS are, however, heterogeneous regarding the
risks for both ischemic and bleeding events. The most recent
European Society of Cardiology non-ST-elevation ACS guide-
lines state that more-intense and prolonged P2Y12 inhibition
may be considered, taking into account the individual
ischemic and bleeding risks.7 However, how these risks
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should be assessed and balanced during DAPT has not been
speciﬁed so far.
In order to facilitate the estimation of bleeding risk, we
have been searching for circulating biomarkers associated
with bleeding during antithrombotic treatment. Recently, we
identiﬁed that plasma level of growth differentiation factor-15
(GDF-15), a member of the transforming growth factor-beta
superfamily, was independently associated with, and con-
tributed to, estimation of the risk of major bleeding events in
ACS on DAPT when measured at the time of initial presen-
tation.8 The association between the GDF-15 level and risk of
major bleeding has also been veriﬁed in patients with atrial
ﬁbrillation receiving different types of oral anticoagulant
therapy.9
In the present study, we hypothesized that a repeated
measurement of GDF-15 level 1 month after an ACS might
provide additional information with regard to risk of major
bleeding beyond the GDF-15 level at the index event.
Methods
Study Population
The PLATelet inhibition and patient Outcomes (PLATO) trial
was a randomized, double-blind trial comparing ticagrelor with
clopidogrel on background aspirin treatment in patients with
ACS, with 6 to 12 months of follow-up. It adhered to the
Declaration of Helsinki and was approved by ethical review
boards. All patients gave their written informed consent to
participate. Ticagrelor treatment was associated with reduc-
tions in ischemic events, including mortality, as compared
with clopidogrel. The design and overall results have been
previously published.1,10 Eligibility criteria of the trial are
found in Table S1.
A biomarker substudy was also part of the study program
that aimed to include all patients at randomization (16 876 of
the 18 624 randomized patients were included). In addition,
repeated blood sampling in a subset of around 4000 patients
also at 1 month after randomization was prespeciﬁed in the
biomarker substudy. In the present study, we included
patients who had samples available for GDF-15 both at
randomization and at 1 month (n=4049). See Figure S1 for a
ﬂow chart of the patient selection. The ﬁrst and last authors
had full access to the data.
Growth Differentiation Factor-15
Samples were obtained by direct venipuncture at randomiza-
tion and at 1 month. Plasma was frozen in aliquots and stored
at 70°C until central analysis at the Uppsala Clinical
Research Center laboratory. Levels of GDF-15 in plasma were
determined with Elecsys electrochemiluminescence
immunoassay on a Cobas Immunoanalyzer system (Roche
Diagnostics, Rotkreuz, Switzerland). The analytical details of
the assay have been published previously.11 Based on
previous studies, elevated level of GDF-15 was deﬁned as
>1800 ng/L.11–13
Outcome
For this study, the end point of interest was major bleeding
not related to coronary artery bypass grafting (CABG)
surgery. The PLATO deﬁnition of non-CABG-related major
bleeding included both life-threatening bleeding (fatal,
intracranial, or intrapericardial bleeding; hypovolemic shock
or severe hypotension attributed to bleeding and requiring
vasopressors or surgery; and decline in hemoglobin of
>50 g/L) and other major bleeding (bleeding leading to
signiﬁcant disability; decline in hemoglobin of 30–50 g/L).
As a secondary end point in this study, we also assessed the
composite of cardiovascular death/myocardial infarction
(MI)/stroke.
End points were assessed from the landmark set at the
1-month follow-up visit, that is, outcomes between random-
ization and 1 month were not considered.
All events were adjudicated by an independent central
adjudication committee.
Statistical Analysis
Patient characteristics are presented as medians and
interquartile range (IQR) for continuous variables and as
percentage and number for categorical variables.
Log2-transformed levels of GDF-15 at baseline and
1 month are presented as box plots, and the individual
relative change in GDF-15 from baseline to 1 month is
presented as a waterfall plot (ie, an ordered bar plot, where
each bar represents an individual patient’s relative change in
biomarker level from baseline to 1 month).
To explore the relationship between GDF-15 levels at
baseline and at 1 month, we ﬁtted Cox models with GDF-15
level entered as restricted cubic splines (unadjusted). The
predicted event rates up until 330 days after baseline, and
300 days after the 1-month visit, are plotted in relation to
GDF-15 concentration at each time point. The x-axis was
truncated at the 1st percentile of baseline GDF-15 at the
lower end and at the 99th percentile at the higher end.
GDF-15 levels (log2 transformed) at 1 month were mod-
eled in an ordinary least squares model, including the
following covariates: log2-transformed baseline GDF-15, age,
sex, smoking status, diabetes mellitus, ACS management
strategy (invasive or noninvasive), hypertension, heart failure,
baseline hemoglobin, baseline estimated glomerular ﬁltration
rate (eGFR), history of gastrointestinal bleeding, and history of
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peripheral arterial disease, where continuous covariates were
entered as restricted cubic splines to account for nonlinear-
ities. Each covariate’s contribution to the model was calcu-
lated as the partial Chi2 statistic minus the covariate’s
degrees of freedom.
Kaplan–Meier estimated event rates for non-CABG-related
major bleeding are plotted from a 1-month landmark up to
300 days according to GDF-15 elevation status at 1 month.
Similar Kaplan–Meier curves from 1 month according to GDF-
15 at 1 month stratiﬁed by baseline GDF-15 elevation status
are presented as well.
Risk of non-CABG-related major bleeding in relation to
GDF-15 at 1 month was also assessed in a Cox model
adjusted for baseline GDF-15 elevation (>1800 ng/L), age
(<75 years versus ≥75 years), impaired renal function (eGFR
<50 mL/min per 1.73 m2), history of gastrointestinal bleed-
ing, and sex, stratiﬁed on presence of anemia at baseline
(deﬁned as baseline hemoglobin <130 g/L in men, <120 g/L
in women). Results are presented as estimated hazard ratio
(HR) and 95% CIs. We assessed the model’s discriminatory
performance using Harrell’s C index and compared it with the
C index of a model where 1-month GDF-15 was excluded.
The statistical software R (version 3.3.2; R Foundation for
Statistical Computing, Vienna, Austria) was used for all
analyses.
Results
Clinical Characteristics
Clinical characteristics at randomization are presented in
Table. A majority of patients were of male sex, and risk factors
such as habitual smoking, hypertension, and diabetes mellitus
were highly prevalent. Approximately one ﬁfth had a history of
MI and 12% a history of previous PCI. When adjusting these
rates to include events occurring after randomization, includ-
ing PCI during the initial hospitalization, 89% had suffered an
MI and 74% had a previous PCI procedure.
Growth Differentiation Factor-15 Levels at
Baseline and 1 Month
Median GDF-15 level at baseline was 1509 ng/L (IQR, 1127–
2106) and at 1 month 1381 ng/L (IQR, 1036–1927). GDF-15
levels were similar in ticagrelor- and clopidogrel-treated
patients both at baseline and at 1 month (data not shown). In
Figure 1A, log2-transformed GDF-15 levels at baseline and
1 month are presented, and, in Figure 1B, the individual
relative change in GDF-15 is shown. Even though GDF-15 levels
were marginally lower at 1 month at the population level, there
were patients with substantial relative increases in GDF-15
and, likewise, patients with substantial relative decreases.
Table. Clinical Characteristics
Characteristic
Total Study Population
Patients With Non-CABG-
Related Major Bleeding
From Baseline During
Follow-up
Patients Without Non-CABG-
Related Major Bleeding From
Baseline During Follow-up
(n=4049) (n=149) (n=3900)
Age, median (IQR) 61 (54–70) 68 (60–74) 61 (53–70)
Male sex 70% (2849) 59% (88) 71% (2761)
Randomized treatment: Ticagrelor 50% (2018) 52% (77) 50% (1954)
Habitual smoker 37% (1509) 32% (48) 37% (1461)
Hypertension 65% (2650) 68% (102) 65% (2548)
Diabetes mellitus 22% (883) 26% (39) 22% (844)
Previous heart failure 5% (219) 7% (11) 5% (208)
Peripheral arterial disease 6% (251) 9% (13) 6% (238)
Chronic kidney disease 8% (312/3908) 17% (25) 8% (287)
MI before index event 20% (794) 19% (28) 20% (766)
Previous MI/Index event=MI 89% (3611) 87% (129) 89% (3482)
PCI before index event 12% (472) 14% (21) 12% (451)
Previous PCI/in-hospital PCI 74% (2981) 83% (124) 73% (2857)
Baseline hemoglobin (g/L), median (IQR) 142 (132–151) 136 (124–145) 142 (132–151)
Baseline eGFR (mL/min per 1.73 m2), median (IQR) 84 (67–101) 73.7 (55.5–94.3) 84.4 (67.3–101.4)
CABG indicates coronary artery bypass graft surgery; eGFR, estimated glomerular ﬁltration rate; IQR, interquartile range; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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Whenmodeling 1-monthGDF-15 levels with an ordinary least
squares model, the most important predictors were: baseline
GDF-15 levels, age, diabetes mellitus, and eGFR (Figure S2), and
this model explained 59% of the variance in 1-month GDF-15.
Major Bleeding in Relation to Growth
Differentiation Factor-15 Levels
From 1 month onward, there were 71 events of non-CABG-
related major bleeding. Increased GDF-15 was associated with
a higher probability of non-CABG-related major bleeding during
follow-up, both when assessed from baseline and from the 1-
month follow-up visit (Figure 2). The spline plot also indicated
that the selected 1800 ng/L cutoff could separate patients at
high risk of bleeding from those with low risk, given that the
slope of the curves tended to increase at around that point.
In patients with GDF-15 levels above 1800 ng/L at
1 month, 3.9% experienced non-CABG-related major bleed-
ing from 1 month up to 300 days thereafter, as compared
with 1.2% in patients with nonelevated GDF-15 at 1 month
(Figure 3). In the multivariable analysis, elevated GDF-15 at
1 month was associated with a 3-fold increased risk of non-
CABG-related major bleeding (HR, 3.38; 95% CI, 1.89–6.06).
The C index was 0.67, compared with 0.63 in a model
excluding 1-month GDF-15. There was also an increased
incidence of the composite end point cardiovascular death/
MI/stroke in patients with elevated GDF-15 (9.2% in those
with GDF-15 >1800 ng/L at 1 month, compared with 4.7%
for patients with nonelevated GDF-15).
Patients who had nonelevated baseline GDF-15 levels and
subsequent elevation of GDF-15 at 1 month were at increased
risk for non-CABG-related major bleeding, compared with
patients who had nonelevated values at both measurements.
In those who had elevated baseline GDF-15 and subsequent
nonelevated GDF-15, the risk of non-CABG-related major
bleeding from 1 month onward was similar as in patients who
had nonelevated levels at both measurements (Figure 4).
Discussion
The main ﬁnding in this study was that the GDF-15 level at
1 month post-ACS provided additional information regarding
A
B
Figure 1. GDF-15 at baseline and at 1 month. A,
Log2-transformedGDF-15 levels. B,Waterfall plot indicating relative
change in GDF-15 levels between baseline and 1 month (please
note that data are truncated at  +100%; a few patients had >100%
relative increase in GDF-15). The plot is an ordered bar plot, where
each patient’s % change in GDF-15 from baseline to 1 month is
plotted. Although GDF-15 levels were only slightly lower on the
population level (A), some patients had substantial relative changes
in GDF-15 (B). GDF-15 indicates growth differentiation factor-15.
Figure 2. Probability of non-CABG-related major bleeding in
relation to GDF-15 assessed from baseline (black) and from the 1-
month follow-up visit (blue). The dashed line indicates a GDF-15
level of 1800 ng/L, which was used as a cutoff to deﬁne GDF-15
elevation in this study. CABG indicates coronary artery bypass
grafting. CABG indicates coronary artery bypass grafting; GDF-15
indicates growth differentiation factor-15.
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risk of non-CABG-related major bleeding beyond that of GDF-
15 levels obtained in the acute phase. When adjusting for
baseline characteristics, including baseline GDF-15 level, an
elevated level of GDF-15 at 1 month was associated with a
3-fold increased risk of non-CABG-related major bleeding
during DAPT after an ACS.
Previous studies have demonstrated an association
between GDF-15 level and risk of bleeding both in patients
with ACS treated with DAPT and in those with atrial ﬁbrillation
treated with oral anticoagulation, when measuring GDF-15
once at the initial presentation.8,9 The present ﬁndings
validate the level of GDF-15 as a useful indicator of risk of
bleeding beyond the acute setting, and indicate that GDF-15
might be a useful marker for monitoring bleeding risk in
patients with coronary artery disease on antithrombotic
treatment.
GDF-15 is, however, also a biomarker associated with
other cardiovascular outcomes. It is independently related to
the composite of recurrent ischemic events and mortality in
ACS,8,12,14 as well as in stable coronary artery disease.15
GDF-15 is also associated with increased risk of the
composite of MI and death in the general population.16–18
Furthermore, it is associated with both myocardial16 and renal
dysfunction.19 Therefore, information on the GDF-15 level
should preferably be used in multivariable clinical prediction
models as one of several risk indicators when balancing the
risk of bleeding and risk of ischemic events in patients on
antithrombotic treatments.
The possible mechanisms underlying the independent
association between GDF-15 and cardiovascular events
have been proposed to be related to its association with
inﬂammation,20 oxidative stress,21 endothelial and myocar-
dial dysfunction,16 atherosclerosis, and aging.22 In response
to tissue injury like MI, there is a further elevation of GDF-
Figure 3. Kaplan-Meier estimates of non-CABG-related major
bleeding from the 1-month follow-up visit according to 1-month
GDF-15 levels (ng/L). CABG indicates coronary artery bypass
grafting.
A
B
Figure 4. Kaplan–Meier estimates of non-CABG-related major
bleeding from the 1-month follow-up visit according to 1-month
GDF-15 levels in (A) patients with nonelevated (≤1800 ng/L)
baseline GDF-15 levels and (B) patients with elevated (>1800 ng/L)
baseline GDF-15 levels. CABG indicates coronary artery bypass
grafting.
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15 that might be related to further activation of inﬂamma-
tory activity and myocardial stress.23,24 With regard to the
more recently discovered bleeding association, the mech-
anism might still be related to frailty and cellular aging.24
However, GDF-15 knockout mice show accelerated throm-
bus formation compared with wild type, and, in vitro, GDF-
15 has been shown to inhibit platelet integrin activation,25
which provides a possible pathophysiological link between
the observed association between GDF-15 levels and
bleeding in patients treated with antithrombotic and/or
anticoagulant therapies.
Currently, there is intense discussion on the duration and
intensity of DAPT and/or the combination of platelet
inhibition with oral anticoagulation in patients with coronary
artery disease. In this situation, there is often a delicate
balance between ischemic risk and bleeding risk that has to
be taken into account, as expressed in recent guidelines.7 In
a substudy of the DAPT trial, a risk score to guide these
decisions was proposed, although this used age as the only
indicator of bleeding risk without providing any estimate of
the discriminatory ability of the ﬁnal model.26 In the present
study, the bleeding signal captured by GDF-15 levels
provided incremental information beyond age and other
clinical factors, both before start of treatment in the acute
phase and when repeated during DAPT treatment in the
chronic phase.
Limitations
There are several limitations to this work. First, patients with
biomarkers at 1 month were a subset of all patients in the
biomarker substudy of PLATO. Second, with a landmark
analysis at 1 month, the risk of time-dependent confounding
is acknowledged. Third, there were relatively few bleeding
events, allowing for adjustment for few variables. Fourth, the
exclusion criteria of the PLATO trial included known risk
factors for bleeding (eg, oral anticoagulant therapy and
thrombocytopenia), which precluded adjustment for these
factors in the present study.
Conclusion
GDF-15 level measured at 1 month after an ACS is related to
risk of bleeding during DAPT and provides additional infor-
mation on bleeding risk beyond the level of GDF-15 at
baseline and other clinical risk indicators of bleeding. GDF-15
level may therefore be useful to support decision making on
the intensity and duration of long-term antithrombotic treat-
ment in patients with coronary artery disease. Further
prospective studies are, though, warranted to assess whether
availability of GDF-15 levels at presentation and during follow-
up after an ACS will improve clinical outcomes.
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Table S1. Eligibility criteria of the PLATO trial. 
Inclusion criteria Exclusion criteria 
• STEMI
(persistent ST-elevation ≥1 mm in ≥2 contiguous leads or
new LBBB), with primary PCI planned
or: 
• NSTE-ACS with ≥2 of the following: 
§ ST-segment changes on ECG indicating ischemia
(ST-depression or transient elevation ≥1 mm in
two or more contiguous leads)
§ Positive biomarker indicating myocardial necrosis
(troponin or CK-MB above the upper limit of
normal)
§ ≥1 of the following:
o ≥60 years of age
o Previous MI or CABG
o Coronary artery disease with ≥50% stenosis
in ≥2 vessels
o Previous ischemic stroke/TIA, carotid
stenosis (≥50%), or cerebral
revascularization
o Diabetes mellitus
o Peripheral artery disease
o Chronic renal dysfunction
• Contraindication to clopidogrel (e.g. hypersensitivity,
moderate or severe liver disease, bleeding, major
surgery within 30 days)
• Oral anticoagulant therapy
• Fibrinolytic therapy planned or within the previous 24
hours
• Concomitant therapy with strong CYP3A inhibitors,
CYP3A substrates with narrow therapeutic indices, or
strong CYP3A inducers
• Index event is an acute complication of PCI
• PCI after index event and before first study dose
• Increased risk of bradycardiac events
• Dialysis required
• Known clinically important thrombocytopenia 
• Known clinically important anemia
• Any other condition that may put the patient at risk or
influence study results in the investigators’ opinion (e.g.
cardiogenic shock, severe hemodynamic instability,
active cancer)
• Participation in another drug or device study within 30
days
• Pregnancy or lactation
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Figure S1. Selection of study population. 
Figure S2. Importance of variables included in the ordinary least squares model for GDF-15 levels at 1 
month, where importance is measured as Chi2 – df. 
 by guest on M
ay 30, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Steg, Robert F. Storey, Agneta Siegbahn and Lars Wallentin
Anders Himmelmann, Hugo A. Katus, Gerald Maurer, José Luis López-Sendón, Philippe Gabriel 
Daniel Lindholm, Emil Hagström, Stefan K. James, Richard C. Becker, Christopher P. Cannon,
With Increased Risk of Major Bleeding
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated
Online ISSN: 2047-9980 
Dallas, TX 75231
 is published by the American Heart Association, 7272 Greenville Avenue,Journal of the American Heart AssociationThe 
doi: 10.1161/JAHA.117.005580
2017;6:e005580; originally published April 14, 2017;J Am Heart Assoc. 
 http://jaha.ahajournals.org/content/6/4/e005580
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 
 for more information. http://jaha.ahajournals.orgAccess publication. Visit the Journal at 
 is an online only OpenJournal of the American Heart AssociationSubscriptions, Permissions, and Reprints: The 
 by guest on M
ay 30, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
